This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
J&J (JNJ) COVID-19 Vaccine Gets Conditional Approval in Europe
by Zacks Equity Research
J&J's (JNJ) single-shot COVID-19 vaccine set to be available in Europe from April.
Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK
by Kinjel Shah
Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.
The Zacks Analyst Blog Highlights: Caterpillar, Goldman Sachs, Johnson & Johnson, The Travelers Companies and Dow
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, Goldman Sachs, Johnson & Johnson, The Travelers Companies and Dow
Here's Why Material ETFs are Sizzling With Opportunities
by Sweta Jaiswal, FRM
Let's look at a few material ETFs that are sizzling with opportunities as the sector is anticipated to remain a hot space for investments in 2021.
5 Top Blue Chip Stocks to Buy as Dow Breezes Past 32,000
by Tirthankar Chakraborty
From muted inflation to the US economy getting better, economically-sensitive stocks are gaining traction, and along with it the Dow. This calls for investing in stocks like Caterpillar (CAT) & Goldman Sachs (GS).
Consumer Discretionary ETFs to Ride Stimulus & Vaccine Optimism
by Sweta Jaiswal, FRM
The reopening of the U.S. economy, coronavirus vaccine rollout and additional stimulus are expected to increasingly drive investors toward the consumer discretionary sector.
Dow Hits New All-Time High Close as Rescue Bill Passes
by Mark Vickery
Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.
Immunovant (IMVT) Gains on a Potential Buyout by Roivant
by Zacks Equity Research
Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.
AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure
by Zacks Equity Research
AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.
Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains
by Zacks Equity Research
Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $157.40, moving +0.83% from the previous trading session.
Momentum ETFs to Gain From the New Stimulus Optimism
by Sweta Jaiswal, FRM
Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.
Top 4 Inverse/Leveraged ETF Areas of Last Week
by Sanghamitra Saha
The first week of March was mixed for Wall Street. The energy sector has been the key winner.
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?
by Kevin Cook
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization
by Urmimala Biswas
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
5 Top-Ranked Mid-Cap ETFs for Outperformance
by Sweta Killa
While large companies are normally known for stability and the smaller ones for growth, mid-caps offer the best of both worlds, simultaneously allowing growth and stability in a portfolio.
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
5 ETF Investing Areas for March to Boost Returns
by Sweta Jaiswal, FRM
Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.
Top ETF Stories of February Worth Watching in March
by Sanghamitra Saha
Though the start of the month was upbeat, rising rate worries triggered a crash at month-end. Can markets rally higher in March on EUA of J&J's vaccine and chances of passage of Biden's stimulus bill?
Travel ETFs Flying High on Vaccine Optimism
by Neena Mishra
Travel stocks will benefit from a return to normalcy
Stock Market News for Mar 3, 2021
by Zacks Equity Research
U.S. markets ended sharply lower on Tuesday led by selloff in tech stocks, a day after recording strong gains, as investors waited for Congress to approve another round of coronavirus relief package.
Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply
by Zacks Equity Research
Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.
The Zacks Analyst Blog Highlights: Johnson & Johnson, UnitedHealth Group, Comcast, QUALCOMM and Micron Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, UnitedHealth Group, Comcast, QUALCOMM and Micron Technology